All In Biotech

Drug Trial Radar · NCT06544707

A Study Designed to Evaluate Tear Production

A Phase 3b Open-Label Study Designed to Evaluate Tear Production Stimulated by 0.003% AR-15512

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

81

Actual

Start

Oct 15, 2024

Primary completion

Jan 30, 2025

Study completion Jan 30, 2025

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).

Conditions

  • Dry Eye Disease

Interventions

  • 0.003% AR-15512 ophthalmic solutionDrug

    Investigational ophthalmic solution administered via topical instillation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1Time frame: Day 1, Minute 0 pre-instillation (Baseline); Day 1, Minute 3 post-instillation
  2. Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 2Time frame: Day 1, Minute 0 pre-instillation (Baseline); Day 1, Minute 3 post-instillation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye Research Foundation

    Newport Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.